-
3 weeks ago | 
pharmatimes.com | John Pinching
Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop (0.1 mg/ml), to slow the progression of paediatric myopia. This approval represents a milestone in childhood eye care and offers a new option for managing myopia in children. Ryjunea is indicated for children aged 3 to 14 years at treatment initiation, with myopia progression of 0.5 d or more per year and severity between -0.5 d and -6.0 d.
-
3 weeks ago | 
pharmatimes.com | John Pinching
Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections (STIs), working in partnership with the NIHR HealthTech Research Centre (HRC) in Diagnostic and Technology Evaluation and the North East Innovation Lab, part of Newcastle Hospitals.
-
3 weeks ago | 
pharmatimes.com | John Pinching
Clinical trial feasibility – prioritising patient motivation Last month, I had the privilege of hosting a webinar for the National Institute for Health and Care Research (NIHR) on ‘Strategies for Growing Patient Recruitment and Retention through Inclusive Research Design and Delivery’ (watch via the QR code).
-
3 weeks ago | 
pharmatimes.com | John Pinching
The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children aged 3 to 17 years with paediatric growth hormone deficiency. The once-weekly treatment, developed by Novo Nordisk, offers an alternative to existing therapies for children experiencing growth failure due to the condition. Growth hormone deficiency affects an estimated 1 in 3,500-4,000 children in the UK, where their bodies do not produce enough of the hormone naturally.
-
3 weeks ago | 
pharmatimes.com | John Pinching
The pharmaceuticals sector plays a pivotal role in society by developing and providing life-saving drugs, advancing medical research and improving global healthcare. At the heart of this industry’s success lies effective leadership, guiding companies through the complex landscape of scientific discovery, regulatory compliance and ethical responsibility.
-
3 weeks ago | 
pharmatimes.com | John Pinching
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Co-ordinator category. As a Clinical Research Co-ordinator (CRC) you play an important role in the success of the study.
-
3 weeks ago | 
pharmatimes.com | John Pinching
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not responded to previous biological treatment or cannot tolerate it. The decision comes less than two months after the Medicines and Healthcare products Regulatory Agency granted marketing authorisation for mirikizumab in the UK.
-
3 weeks ago | 
pharmatimes.com | John Pinching
The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga (dapagliflozin) as a treatment option for chronic kidney disease (CKD) in a broader patient population. The decision follows a review of additional clinical data, including real-world evidence and previous trial results, which demonstrated the drug’s efficacy in treating CKD. CKD affects more than 7 million people in the UK, with 1 million unaware they have the condition.
-
1 month ago | 
pharmatimes.com | John Pinching
The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in England as a treatment for primary IgA nephropathy. The decision follows UK regulatory approval and is based on results from the phase 3 PROTECT trial. NICE’s guidance states that sparsentan can be prescribed to adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.
-
1 month ago | 
pharmatimes.com | John Pinching
With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD) is set to revolutionise early diagnosis with its patented Cortical Disarray Measurement (CDM®) technology. The software analyses standard MRI scans to provide an objective measure of neurodegeneration, offering a more precise way to assess brain health. Following FDA 510(k) clearance and UKCA self-certification, OBD will now roll out its technology commercially across healthcare sectors in the UK and US.
